CRANBURY, N.J., May 31 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD - News) announced today the pricing of its initial public offering (IPO) of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Amicus has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock to cover over- allotments, if any. All shares in the offering will be sold by the Company and are expected to begin trading today on the NASDAQ Global Market under the trading symbol "FOLD."
Morgan Stanley & Co. Incorporated and Merrill Lynch & Co. served as joint book-runners for the offering, with J.P. Morgan Securities Inc., Lazard Capital Markets LLC, and Pacific Growth Equities, LLC acting as co-managers. The offering is expected to close on or about June 5, 2007, and is subject to the satisfaction of customary closing conditions.
Amicus filed a registration statement, which has been declared effective by the Securities and Exchange Commission (SEC). A copy of the final prospectus relating to the offering may be obtained by contacting Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York 10014, attention: Prospectus Department, or by e-mailing firstname.lastname@example.org or contacting Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080, or by calling 212-449-1000. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus is currently conducting Phase II clinical trials of Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The company is currently conducting Phase I clinical trials of AT2220 for the treatment of Pompe disease.
Safe Harbor Statement
This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates," or the negation thereof, or similar expressions, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Amicus to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For those statements, Amicus claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. Amicus will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Source: Amicus Therapeutics